Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells

Immunopharmacology and Immunotoxicology

Volumn 18, Issue 1, 1996, Pages 59-72

  Shannon, Edward J ^a   Sandoval, Felipe ^a   Long, Gillis W ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL LINE; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0029922290     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979609007110     Document Type: Article

References (22)

1. Makanokaweyoon S, Limson-Pobre RNR, Moreia AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.
2. Moreira A, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
3. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
4. Nishimura K, Hashimoto Y, Iwasaki S. Enhancement of phorbol ester-induced production of tumor necrosis factor α by thalidomide. 1994;199(2):455-60.
5. Faigle JW, Kerberle HR, Schmid K. The metabolic fate of thalidomide. Experentia 1962;18:389.
6. Gunzler V, Hanauske-Abel HM, Tschank G, Schulte-Wissermann H. Immunological effects of thalidomide: Inactivity of the drug and several of its hydrolysis products in mononucleocyte proliferation tests. Amerein-Forsch/Drug Res. 1986;36(11):1138-41.
7. Lonnemann G, Endres S, Van der Meer JWM, Cannon JG, Koch KM Dinarello CA. Differences in the synthesis and kinetics of release of interleukin 1α, interleukin 1β and tumor necrosis factor from human mononuclear cells. Eur J Immunol 1989;19:1531-36.
8. Barns PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor nercosis factor production in patients with leprosy. Inf Immun. 1992;60(4):1441-46.
9. Shannon EJ, Ejigu M, Haile-Mariam HS, Berhan TY, Tasesse G. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in peripheral blood. Lepr Rev 1992;63:5-11.
10. Bhattacharya SN, Chattopadhaya D, Saha K. Tumor necrosis factor: status in reactions in leprosy before and after treatment. Int J of Dermatology 1993;32(6)436-39.
11. th International Leprosy Congress, p. 101A Orlando Aug 29-Sept 4, 1993;11.
12. Sarno EN, Grau GE, Vieira LMM, Nery JA. Serum levels of tumor necrosis factor-α and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991;84:103-8.
13. Tracey KJ, Cerami A. Cachectin/tumor necrosis factor and other cytokines in infectious disease. Curr Opin Immunol 1989;1:454-61.
14. Jacob CO. Tumor necrosis factor a in autoimmunity: pretty girl or old witch? Immunol Today 1992;13(4):121-25.
15. Leibovich SJ, Polverini PJ, Shepard HM et al. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-α. Nature 1987;329:630-32.
16. Fràter-Schröder M, Risau W, Hallmann R, Gautschi P, Böhlen P. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro,is angiogenic in vivo. Proc Natl Acad Sci 1987;84:5277-81.
17. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-α in angiogensis. Amer J Path 1992;140(3):539-44.
18. Piguet PF, Grau GE, Vassalli P. Subcutaneous perfusion on tumor necrosis factor local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Amer J Path 1990;136(1):103-10.
19. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 by glucose-modified proteins: role in normal tissue remodeling. Science 1988;249:1546-48.
20. Shalaby MR, Palladino MA, Hirabayashi SE, Eessalu TE, Lewis GD, Shepard HM, Aggarwal BB. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J of Leuk Biol 1987;41:196-204.
21. Otsuka Y, Nagano K, Nagano K, Hori K, Ichi-J, Ishi-O, Hayashi H, Watanabe N, Niitsu Y. Inhibition of neutrophil migration by tumor necrosis factor: ex vivo and in vivo studies in comparison with in vitro effects. J Immunol 1990;145:2639-43.
22. Shibata, Y., Sasaki, K., Nishimura, K., Hasimoto, Y., Iwasaki, S. Enhacement of phorbol ester-induced production of tumor nercosis factor-α by 2, 6-dimethyphenyphthalimide. Biol. Phar. Bull. 1994;17(11)1532-1534.